Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

News Releases

Date Title and Summary
Toggle Summary electroCore to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 23
Conference Call to be Held at 4:45pm Eastern Time BASKING RIDGE, N.J. , March 19, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2019
Toggle Summary electroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies
Agreement opens reimbursement pathway for thousands of patients with migraine and cluster headache BASKING RIDGE, N.J. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Ascent Health Services on behalf of
Toggle Summary electroCore Provides Business Update and Select Financial Guidance
BASKING RIDGE, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary unaudited guidance for the fourth
Toggle Summary electroCore Announces Board of Directors Transition
BASKING RIDGE, N.J. , Dec. 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox , will resign from the Board effective March 31, 2020 . Ms.
Toggle Summary NICE Recommends the Use of gammaCore for the Treatment of Cluster Headache in the NHS
NICE has today published a medical technologies guidance document recommending the use of gammaCore within the NHS for the acute and preventive treatment of cluster headache in the U.K. LONDON and BASKING RIDGE, N.J. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a
Toggle Summary electroCore to Present at the Two December Investor Conferences
BASKING RIDGE, N.J. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger , Chief Executive Officer, will present  a corporate overview and host investor meetings at the Evercore ISI HealthCONx 
Toggle Summary electroCore Announces Third Quarter 2019 Financial Results
Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions Company to host conference call and webcast today, November 13 , at 4:30pm ET BASKING RIDGE, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Toggle Summary electroCore to Announce Third Quarter 2019 Financial Results on Wednesday, November 13th
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter and nine-months ended September 30,
Toggle Summary electroCore Appoints Medical Technology Veteran Daniel S. Goldberger as Chief Executive Officer
BASKING RIDGE, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive Officer, effective October 1 . Mr.
Toggle Summary electroCore Provides Update on 510(k) Submission Seeking Expanded Indication for gammaCore™
Additional information requested by FDA; Premium 2 trial progressing as planned   BASKING RIDGE, N.J. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR, or the “Company”), a commercial-stage bioelectronic medicine company, today announced that the U.S.